GB1194548A - Improvements in Compositions Comprising beta-Adrenolytics - Google Patents

Improvements in Compositions Comprising beta-Adrenolytics

Info

Publication number
GB1194548A
GB1194548A GB5355067A GB5355067A GB1194548A GB 1194548 A GB1194548 A GB 1194548A GB 5355067 A GB5355067 A GB 5355067A GB 5355067 A GB5355067 A GB 5355067A GB 1194548 A GB1194548 A GB 1194548A
Authority
GB
United Kingdom
Prior art keywords
lower alkyl
group
hydroxy
groups
alkyl groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5355067A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CH Boehringer Sohn AG and Co KG
Boehringer Ingelheim GmbH
Original Assignee
CH Boehringer Sohn AG and Co KG
Boehringer Ingelheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CH Boehringer Sohn AG and Co KG, Boehringer Ingelheim GmbH filed Critical CH Boehringer Sohn AG and Co KG
Publication of GB1194548A publication Critical patent/GB1194548A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1,194,548. #-adrenolytic compositions. BOEHRINGER INGELHEIM G.m.b.H. 24 Nov., 1967 [25 Nov., 1966, 5 Sept., 1967], No. 53550/ 67. Heading A5B. Compositions for treating angina pectoris comprise a #-andrenolytic and a coronary dilator of the general formula: in which R 1 is an amino group substituted by two mono- or dihydroxylower (C 1-6 ) alkyl groups or by two lower acyloxylower alkyl groups; a morpholino, pyrrolidin-l-yl, piperazin-1-yl; 1, 2, 5, 6-tetrahydropyrid-1-yl or piperidino group, optionally substituted by one or two lower alkyl or hydroxy groups; or a lower alkyl or alkylamino group, an amino group substituted by lower alkyl or hydroxy lower alkyl group or an amino group substituted by an aryl lower alkyl group and a hydroxy lower alkyl group; R 2 is piperidino, 1, 2, 5, 6-tetrahydropyrid-1-yl, morpholino, piperazin-1-yl or pyrrolidin-1-yl group optionally substituted by one or two lower alkyl or hydroxy groups, a lower alkoxy or alkylthio group, an amino group substituted by two mono- or dihydroxy lower alkyl groups or by two lower acyloxy lower alkyl groups; or an amino group substituted by a lower alkyl group and a hydroxy lower alkyl group or by an aryl lower alkyl group and a hydroxy lower alkyl group; and A is -N=C(R 3 )-N=CR 4 )- or -N =C(R 3 )-C(R 4 )=N- or -S(CH 2 ) n - or -S(CH 2 ) n - where R 3 is an amino group substi- # O tuted by two mono or dihydroxy lower alkyl groups or by two lower acyloxyl lower alkyl groups; or a phenyl, thienyl or furyl group carrying one or more halogen atoms or lower alkyl groups, R 4 has the same meanings as R 1 and R 2 and n is 2 or 3. Preferred #-adrenolytics are those of the formula ArO-CH 2 -CHOHCH 2 NHR in which Ar is phenyl, naphthyl, tetrahydronaphthyl or indaryl, optionally substituted with one or more lower alkyl groups, -OF 3 , -NH 2 , -CN, halogen atoms, lower alkoxy, alkenyloxy, alkynyloxy, acyloxy, acyl, alkoxyalkyl, alkenyl, alkynyl, alkylthio or mono or dialkylamino groups or -NO 2 , -OH or -O-CH 2 -O- groups; and R is a C 1-6 alkyl group or a C 7-10 aralkyl group, and the compounds 1-(4-methanesulphonamidophenyl)-1- hydroxy-2-isopropylaminoethane and 1-(4-nitrophenyl)-1-hydroxy-2-isopropylaminoethane The compositions may be in conventional (forms for oral, parenteral and rectal administration comprising the active constituents (preferably as acid addition salts) and conventional excipients.
GB5355067A 1966-11-25 1967-11-24 Improvements in Compositions Comprising beta-Adrenolytics Expired GB1194548A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEB0090017 1966-11-25

Publications (1)

Publication Number Publication Date
GB1194548A true GB1194548A (en) 1970-06-10

Family

ID=6985072

Family Applications (2)

Application Number Title Priority Date Filing Date
GB3899/70A Expired GB1201460A (en) 1966-11-25 1967-11-24 IMPROVEMENTS IN COMPOSITIONS COMPRISING beta-ADRENOLYTICS
GB5355067A Expired GB1194548A (en) 1966-11-25 1967-11-24 Improvements in Compositions Comprising beta-Adrenolytics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB3899/70A Expired GB1201460A (en) 1966-11-25 1967-11-24 IMPROVEMENTS IN COMPOSITIONS COMPRISING beta-ADRENOLYTICS

Country Status (5)

Country Link
BE (1) BE707050A (en)
DE (1) DE1617336C2 (en)
FR (1) FR7514M (en)
GB (2) GB1201460A (en)
IE (1) IE31963B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937834A (en) 1970-10-02 1976-02-10 Ciba-Geigy Corporation Pharmaceutical preparations
EP0362645A2 (en) * 1988-10-01 1990-04-11 Dr. Karl Thomae GmbH Use of pteridines in the prevention of the primary and secondary resistance during chemotherapy, and medicaments containing these compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937834A (en) 1970-10-02 1976-02-10 Ciba-Geigy Corporation Pharmaceutical preparations
EP0362645A2 (en) * 1988-10-01 1990-04-11 Dr. Karl Thomae GmbH Use of pteridines in the prevention of the primary and secondary resistance during chemotherapy, and medicaments containing these compounds
EP0362645A3 (en) * 1988-10-01 1992-03-25 Dr. Karl Thomae GmbH Use of pteridines in the prevention of the primary and secondary resistance during chemotherapy, and medicaments containing these compounds

Also Published As

Publication number Publication date
IE31963B1 (en) 1973-03-07
IE31963L (en) 1968-05-25
DE1617336C2 (en) 1982-07-01
DE1617336A1 (en) 1970-12-10
FR7514M (en) 1969-12-15
GB1201460A (en) 1970-08-05
BE707050A (en) 1968-05-24

Similar Documents

Publication Publication Date Title
KR860000281A (en) Method for preparing 7-amino-1-cyclopropyl-6,8-dihalogeno-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
ES2194986T3 (en) CARBONIL-PIPERAZINYL AND PIPERIDINYL COMPOUNDS THAT INHIBIT THE FARNESIL-PROTEIN-TRANSFERASA.
ATE120955T1 (en) BENZYLIDENE-MALONONITRILE DERIVATIVES FOR INHIBITING PROLIFERATIVE PROCESSES IN MAMMAL CELLS.
SE8204237D0 (en) CARBOSTYRIC ASSOCIATIONS, COMPOSITIONS CONTAINING THESE AND THE PROCEDURES FOR PREPARING THEREOF
GB1335493A (en) 1a-beta-d arabinofuranosyl cytosine derivatives and process for making same
KR900018112A (en) Excitatory amino acid antagonists
ES390924A1 (en) Esters of substituted nicotine acids
GB1194548A (en) Improvements in Compositions Comprising beta-Adrenolytics
GB1342520A (en) Alpha-alkyl-substituted benzyl or thenyl-benzyloxy derivatives of amines
ES327089A1 (en) Dithiosemicarbazones
ES8604102A1 (en) Substituted alpha-(ethyl)-alpha-(phenyl)-(omega-(dialkylamino)-alkoxy)-benzyl alcohols, their acid addition salts and quaternary salts, process for their preparation, as well as medicines containing these compounds.
IE56209B1 (en) Piperidinedione derivatives,processing anti-arrythmic activity,for protecting the myocardium,process for their preparation and pharmaceutical compositions containing said derivatives
GB1435916A (en) Pharmaceutical weight-reducing compositions
GB1153424A (en) Pharmaceutical Compositions
SE7609909L (en) NEW PENICILLINES AND PROCEDURES FOR MANUFACTURING THEM
GB1191971A (en) 2-Amino-6,7-Distributed-4H-1,3-Benzothiazine-4-Ones as Bronchodilators
GB1053843A (en)
GB1058243A (en) Thiophen derivatives
ES385091A1 (en) Beta-(2,4,6-triiodo-3-acetamidinophenyl)-propionic acids
ES391993A1 (en) Basically substituted alkyl theophyllines
GB1270831A (en) Di-hydro triazine derivatives and processes for their manufacture
FR2371199A1 (en) MEDICINAL PRODUCT INTENDED TO INTENSIFY THE GROWTH OF HAIR AND HAIR
JPS52118474A (en) Alpha-substituted aminoalkanyol-3,4-dihydrocarbostyril derivatives and method of preparing the same
ES291187A1 (en) Substituted piperazines
JPS5283581A (en) 2,4-disubstituted-6-benzalhydrazino-s-triazines and acid addition sal ts thereof

Legal Events

Date Code Title Description
PS Patent sealed
PE20 Patent expired after termination of 20 years